![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Smoking cessation in patients undergoing treatment
for head and neck cancer
Smoking is a risk factor for many disease processes and adds
a great burden on our healthcare system. It is a major public health issue in
New Zealand with a prevalence of 21%.1 Smoking
and alcohol are independent risk factors for cancer of the aerodigestive tract
and their synergistic effect is well
documented.2–7 Techniques are available
to assist people to quit smoking. Advice on cessation of smoking is part of our
management of head and neck cancer patients. We present here results of our
study determining the effectiveness of smoking cessation strategy, contributing
factors, and long-term abstinence in these patients.
Consecutive patients who were smokers at the time of
diagnosis of head and neck cancer were culled from our prospective head and neck
database. Demographic data, diagnosis, tumour location and risk factors were
obtained. The patients were sent a questionnaire to document their smoking
habits, factors that influenced cessation and the interval of abstinence. A
follow-up telephone interview was conducted for non-responders.
Fifty-six (49%) of the 114 consecutive patients had
deceased. The remaining 58 patients had cancer in the oral cavity (n=31),
salivary gland (n=7), oropharynx (n=5), bone (n=4) and paranasal sinus (n=3),
metastatic skin cancer (n=7), and neck metastasis with unknown primary (n=1). 50
(86%) of the 58 patients responded to the questionnaire. Of those who responded
37 (74%) stopped smoking, with 27 (75%) doing so around the time of diagnosis
and treatment.
The most influential factor for quitting smoking were the
diagnosis of cancer (n=20), hospitalisation (n=14), medical advice (n=13),
family advice (n=8), Quit Line (n=2), and nicotine replacement therapy (n=1).
The latter two factors were ranked 6 and 5 times respectively as the least
important factor influencing their quitting smoking. 18 (49%) of the 37
participants who stopped smoking restarted, and the remainder continued to
abstain. Of those who restarted smoking, 5 (28%) did so within 1 month, 7 (39%)
1–12 months, 2 (11%) 1–5 years, and 4 (22%) did not mention the
interval.
We infer that most patients undergoing treatment for head
and neck cancer quit smoking in response to a personal “crisis”,
i.e. the diagnosis. This is reinforced by the non-smoking hospital environment
and consistent medical and family advice. This finding may have implications to
mechanisms leading to successful quitting in other patients who smoke. However,
strategies are needed to reduce the high rate of restarting smoking for
successful quitters in head and neck cancer patients.
Swee T Tan
Consultant, Plastic & Cranio-Maxillofacial Surgeon, Head & Neck and Skull Base Surgery/Oncology Programme, Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital—and Director, Gillies McIndoe Research Institute; and Professor in Plastic Surgery, University of Otago, Wellington swee.tan@huttvalleydhb.org.nz Kunaal Rajpal
Formerly House Surgeon, Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital, Wellington Craig A Mackinnon
Consultant, Plastic & Cranio-Maxillofacial Surgeon, Head & Neck and Skull Base Surgery/Oncology Programme, Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital Wellington References:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |